PGBioclin
ActiveSummary
PGBioclin has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5,495 and a net result of €90,119. Equity has been shrinking by about 18% per year since 2020. If that trend continues, it turns negative around financial year 2027. Its solvency ranks better than 15% of 617 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.9% (low).
Overview
Official details
Source: KBO- Status
- Active since 26-05-2020 Normal situation
- Activity
- Other research and development on natural sciences NACE 72109and 1 other
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.9%
- Gross margin
- €135,818
- ▼ 55.2%
- Turnover
- ≈ €340,000
- estimated
- Profit
- €90,119
- ▼ 61.4%
- Equity
- €5,495
- ▼ 96.2%
- Total assets
- €208,043
- ▲ 16.2%
Score breakdownraises riskNo registered site in the KBOFounded in 2020lowers riskSector: Scientific research and development (NACE 72)Size: total assets €208,043Show the evidence
Checked score
About 9 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro). It does better than 19% of them on solvency, 3% on liquidity, 90% on profitability and 7% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 6 accounts on average 123 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
- Caution: Equity fell in 2025from €144,375 to €5,495 ▼ 96.2% View
- Caution: Lower solvency than 84% of companies in research and developmentsector median 60.4% · 617 companies 2.6% View
- Positive: Always filed on timeaccounts within the deadline every year 6 years View
- Positive: 6 profitable years in a rowprofit 2025: €90,119 6 years View
Recent changes
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as PGBioclin: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €152,000 and €230,000, founded between 2018 and 2021.
| Company | Total assets | Gross margin |
|---|---|---|
| PGBioclin Limbourg | €208,043 | €135,818 |
| Laboratoire d'invention européen 2020 Sint-Agatha-Berchem | €168,383 | €128,171 |
| VDW Consults Kampenhout | €220,025 | €135,470 |
| M3bio Consulting Beveren-Kruibeke-Zwijndrecht | €229,772 | €180,569 |
| SCouP Jalhay | €178,171 | €59,889 |
| CUBATIK Crisnée | €151,712 | €88,630 |
| JTA CONSULTING Anderlecht | €189,416 | €103,045 |
Key facts about PGBioclin
- What is the company number of PGBioclin?
- The company number of PGBioclin is 0747.635.715. The VAT number is the same number with BE in front: BE 0747.635.715.
- Where is PGBioclin based?
- The registered office is at Pirhettes 21, 4834 Limbourg.Company details
- What does PGBioclin do?
- According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
- What is the legal form of PGBioclin?
- The legal form of PGBioclin is Private limited company (BV).
- When was PGBioclin founded?
- PGBioclin was founded on 26-05-2020.
- Is PGBioclin still active?
- Yes, PGBioclin is an active enterprise in the KBO register.
- What is the turnover of PGBioclin?
- The turnover in financial year 2025 is ≈ €340,000. This figure is estimated from the gross margin of €135,818 and 2,215 comparable companies of the same size. It probably lies between €230,000 and €530,000. It is a rough estimate.Financials
- Is PGBioclin profitable?
- In financial year 2025, PGBioclin made a profit of €90,119.
- Where can I find the annual accounts of PGBioclin?
- PGBioclin filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PGBioclin due?
- PGBioclin must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.